Revolution Medicines (RVMD) call put ratio 3.3 calls to 1 put after presented the full results from the Phase 3 RASolute 302 trial evaluating daraxonrasib at ASCO

Revolution Medicines (NASDAQ: RVMD) 30-day option implied volatility is at 58; compared to its 52-week range of 40 to 125. Call put ratio 3.3 calls to 1 put after the company presented the full results from the Phase 3 RASolute 302 trial evaluating daraxonrasib at ASCO.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• Meta pauses an AI training program that tracks employees' keystrokes after a companywide leak - Insider
• A. O. Smith CEO Stephen Shafer named chairman